WallStSmart

Cardiol Therapeutics Inc Class A (CRDL)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

TEVA leads profitability with a 8.2% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 73/100 (B).

CRDL

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0

TEVA

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 7.5Value: 10.0Quality: 4.8
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CRDL.

TEVAUndervalued (+39.4%)

Margin of Safety

+39.4%

Fair Value

$56.63

Current Price

$29.46

$27.17 discount

UndervaluedFair: $56.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRDL0 strengths · Avg: 0/10

No standout strengths identified

TEVA4 strengths · Avg: 8.3/10
Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
27.3%8/10

Strong operational efficiency at 27.3%

EPS GrowthGrowth
40.0%8/10

Earnings expanding 40.0% YoY

Free Cash FlowQuality
$1.02B8/10

Generating 1.0B in free cash flow

Areas to Watch

CRDL4 concerns · Avg: 3.8/10
Price/BookValuation
13.1x4/10

Trading at 13.1x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$103.42M3/10

Smaller company, higher risk/reward

TEVA1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CRDL

CRDL has a balanced fundamental profile.

Bull Case : TEVA

The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : CRDL

The primary concerns for CRDL are Price/Book, Revenue Growth, EPS Growth.

Bear Case : TEVA

The primary concerns for TEVA are Altman Z-Score.

Key Dynamics to Monitor

CRDL carries more volatility with a beta of 0.73 — expect wider price swings.

TEVA is growing revenue faster at 11.4% — sustainability is the question.

TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TEVA scores higher overall (73/100 vs 17/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardiol Therapeutics Inc Class A

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?